Orum Therapeutics is developing a novel class of antibody-drug conjugates (ADCs) that utilize their proprietary TPD² technology for selective protein degradation. This approach aims to enhance the efficacy and safety of treatments by targeting previously undruggable proteins, thereby improving patient outcomes in disease management.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional antibody-drug conjugates (ADCs) face limitations in efficacy and safety due to non-selective targeting and off-target effects, hindering their ability to effectively degrade disease-causing proteins within specific cells. This can lead to suboptimal patient outcomes and increased toxicity.
Solution
Orum Therapeutics is developing a novel class of ADCs using its proprietary TPD² (Targeted Protein Degradation²) technology. This technology enables selective protein degradation within target cells, enhancing efficacy and safety compared to conventional ADCs. By conjugating antibodies to protein degraders, Orum's approach aims to target previously undruggable proteins, expanding the therapeutic landscape and improving patient outcomes in disease management. The TPD² platform is designed to improve upon the efficacy, safety, and half-life of conventional targeted protein degraders.
Target Audience
The primary target audience includes patients with diseases that are currently difficult to treat due to limitations in existing therapies, as well as pharmaceutical companies seeking innovative approaches to drug development.
Features
- TPD² technology for cell-selective protein degradation
- Antibody-drug conjugates designed for enhanced efficacy and safety
- Targeting of previously undruggable proteins
- Pipeline of differentiated products combining protein degraders with antibody precision